

Haematologica  
HAEMATOL/2017/183400  
Version 3

Usefulness of Initial plasma dabigatran concentration to predict  
rebound after reversal

Nicolas Gendron, Juliette Gay, Marine Lemoine, Pascale Gaussem,  
Agnès Lillo-Le Louet, and David M. Smadja

Disclosures: JG and ML have nothing to declare. NG declares consulting fees from Bayer. ALL declares consulting fees from Sanofi. DMS declares consulting fees from Bristol-Myers-Squibb, Boehringer Ingelheim, Bayer and Léo Pharma. PG declares consulting fees from Bayer and Sanofi.

Contributions: NG wrote the paper. NG, JG, ML and AL analyzed the data. PG provided helpful suggestion and contributed to paper writing. D.M.S. supervised the research, analyzed the data, and wrote the paper.